Financials in USD. Standardized financial statements.
A compact view of how Lineage Cell Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $14.56M | $9.50M | $8.95M | $14.70M | $3.90M | $773,000 | $1.48M | $1.42M | $1.79M | $2.25M |
| Revenue Growth? | +53.2% | +6.2% | -39.2% | +277.4% | +404.0% | -47.7% | +4.4% | -21.0% | -20.4% | 0.0% |
| Cost of Revenue? | $845,000 | $334,000 | $671,000 | $728,000 | $1.43M | $385,000 | $412,000 | $302,000 | $168,000 | $358,000 |
| Gross Profit? | $13.71M | $9.16M | $8.27M | $13.97M | $2.47M | $388,000 | $1.07M | $1.11M | $1.62M | $1.89M |
| Gross Margin? | +94.2% | +96.5% | +92.5% | +95.0% | +63.4% | +50.2% | +72.1% | +78.7% | +90.6% | +84.1% |
| Operating Expenses? | $35.49M | $30.64M | $33.01M | $36.49M | $51.68M | $26.84M | $39.94M | $42.11M | $42.28M | $60.86M |
| Operating Income? | -$21.78M | -$21.48M | -$24.73M | -$22.52M | -$49.21M | -$26.45M | -$38.88M | -$41.80M | -$38.90M | -$58.97M |
| EBITDA? | -$21.08M | -$20.87M | -$24.04M | -$21.79M | -$48.34M | -$24.41M | -$35.88M | -$37.72M | -$37.36M | -$54.21M |
| Income Before Tax | -$68.65M | -$18.58M | -$23.28M | -$25.81M | -$43.27M | -$21.92M | -$19.23M | -$47.13M | -$23.29M | $18.62M |
| Income Tax Expense | -$5.11M | $0 | -$1.80M | $541,000 | $0 | -$1.24M | -$7.41M | -$346,000 | $0 | $0 |
| Net Income? | -$63.53M | -$18.61M | -$21.49M | -$26.27M | -$43.02M | -$20.65M | -$11.71M | -$45.99M | -$19.98M | $33.57M |
| EPS? | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 | $-0.36 | $-0.17 | $0.35 |
| Diluted EPS? | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 | $-0.14 | $-0.08 | $-0.36 | $-0.17 | $0.34 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality